Skin & Cosmetic
PT-141
FDA-approved Bremelanotide (Vyleesi 2019) — acts via central nervous system melanocortin pathways.
Evidence: 2 articles
Goals: 1
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Level
Clinical Trial - Human
2 studies published
Pharmacology
Molecular Weight
~1,025 Da
Half-Life
~2.7 hours (subcutaneous)
Bioavailability
Subcutaneous autoinjector; nasal formulation studied but not approved